These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6702716)

  • 21. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Yordan E; Beecham J
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited activity of ICRF-159 in advanced acute leukemia.
    Bakowski MT; Prentice HG; Lister TA; Malpas JS; McElwain TJ; Powles RL
    Cancer Treat Rep; 1979 Jan; 63(1):127-9. PubMed ID: 369684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
    Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
    Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix.
    Morris M; Brader KR; Levenback C; Burke TW; Atkinson EN; Scott WR; Gershenson DM
    J Clin Oncol; 1998 Mar; 16(3):1094-8. PubMed ID: 9508195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of mitomycin-C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix.
    Baker LH; Opipari MI; Izbicki RM
    Cancer; 1976 Dec; 38(6):2222-4. PubMed ID: 63314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
    Corder MP; McFadden DB; Bell SJ
    Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of radiotherapy with and without razoxane (ICRF 159) in the treatment of soft tissue sarcomas.
    Hellmann K; Ryall RD; Macdonald E; Newton KA; James SE; Jones S
    Cancer; 1978 Jan; 41(1):100-7. PubMed ID: 414829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.
    McGuire WP; Arseneau J; Blessing JA; DiSaia PJ; Hatch KD; Given FT; Teng NN; Creasman WT
    J Clin Oncol; 1989 Oct; 7(10):1462-8. PubMed ID: 2674333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer.
    Bakowski MT; Macdonald E; Mould RF; Cawte P; Sloggem J; Barrett A; Dalley V; Newton KA; Westbury G; James SE; Hellmann K
    Int J Radiat Oncol Biol Phys; 1978; 4(1-2):115-9. PubMed ID: 344287
    [No Abstract]   [Full Text] [Related]  

  • 30. Further experience with rezoxane (ICRF 159; -- NSC --129943) in treating Kaposi's sarcoma.
    Olweny CL; Sikyewunda W; Otim D
    Oncology; 1980; 37(3):174-6. PubMed ID: 7360489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of ICRF-187 using a daily for 3 days schedule.
    Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
    Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's sarcoma (AIDS-KS).
    Chachoua A; Green M; Wernz J; Muggia F
    Invest New Drugs; 1989 Nov; 7(4):327-31. PubMed ID: 2513285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.
    Muss HB; Sutton GP; Bundy B; Hatch KD
    Am J Clin Oncol; 1985 Aug; 8(4):312-5. PubMed ID: 3909803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
    Herman EH; Ferrans VJ; Bhat HB; Witiak DT
    Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix.
    Arseneau JC; Bundy B; Dolan T; Homesley H; DiSaia PJ
    Am J Clin Oncol; 1982 Feb; 5(1):61-4. PubMed ID: 6211087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
    Stehman FB; Blessing JA; McGehee R; Barrett RJ
    J Clin Oncol; 1989 Dec; 7(12):1892-5. PubMed ID: 2685182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined treatment of lung carcinoma. Report on a prospective randomized study with radiotherapy and ICRF 159 (1,2-(3,5-dioxopiperazines-lyl)propane) (author's transl)].
    Hassenstein E; Rhomberg W
    Med Klin; 1977 Feb; 72(5):171-5. PubMed ID: 403395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
    Muss HB; Bundy B; DiSaia PJ; Stehman FB; Beecham J
    Am J Clin Oncol; 1984 Dec; 7(6):741-4. PubMed ID: 6528869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
    Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.